Phase 3 Readout

APLS: Phase 3 Topline: An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Effic

Name: Phase 3 Topline: An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Effic
Start: 2027-07-01
End: 2027-07-01

July 1, 2027. BioSniper AI can trace the company-impact path without requiring you to write the research question.

Event date: July 1, 2027
Company: Apellis Pharmaceuticals, Inc. (APLS)

BioSniper AIPage evidence connected

Prepared research question

What could this event change, and which evidence should be watched next?

Run cited research

Traceable citations · Unknowns marked

Phase 3 Readout~month

Phase 3 Topline: An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Effic

July 1, 2027

APLS overview →

Company: Apellis Pharmaceuticals, Inc. (APLS)
Indication: C3 Glomerulopathy; C3G; IC-MPGN